- Annual report 2008 February 19, 2009 - Annual General Meeting March 27, 2009 Den Sorte Diamant 4.00 p.m. Søren Kierkegaards Plads 1221 Copenhagen K, Denmark - Three-month interim report (Q1) 2009 May 1, 2009 - Six-month interim report (Q2) 2009 August 18, 2009 - Nine-month interim report (Q3) 2009 November 19, 2009 ALK-Abelló A/S Jens Bager President and CEO For further information please contact: Per Plotnikof, Head of Investor Relations, tel. +45 4574 7527 About ALK ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) - a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX®, was launched in Europe in 2007. ALK has entered into a strategic partnership regarding the tablet programme with Schering-Plough for North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX.com.